Circular RNA For Translation In Eukaryotic Cells
AssigneeMassachusetts Institute of Technology
InventorsDaniel G. Anderson, Robert Alexander Wesselhoeft, Piotr S. Kowalski
Life of this patent
Estimating the term…
Abstract
Circular RNA and methods and constructs for engineering circular RNA are disclosed. In some embodiments, the circular RNA includes the following elements arranged in the following sequence: a) a 3′ Group I self-splicing intron fragment, b) an internal ribosome entry site (IRES), c) a protein coding region or noncoding region, and d) a 5′ Group I self-splicing intron fragment.
Claims29
A pharmaceutical composition comprising an immunoquiescent circular RNA, the circular RNA comprising the following elements arranged in the following sequence:
- a) an exon sequence of a 3′ Group I self-splicing intron-exon,
- b) an internal ribosome entry site (IRES),
- c) a protein coding region that encodes a therapeutic protein, and
- d) an exon sequence of a 5′ Group I self-splicing intron-exon.
A method of treating a disease in a subject, the method comprising administering a pharmaceutical composition comprising an immunoquiescent circular RNA, wherein the circular RNA comprises the following elements arranged in the following sequence:
- a) an exon sequence of a 3′ Group I self-splicing intron-exon,
- b) an internal ribosome entry site (IRES),
- c) a protein coding region that encodes a therapeutic protein, and
- d) an exon sequence of a 5′ Group I self-splicing intron-exon.
Dependencies are inferred from the claim text.